2. Search Result
Search Result
Results for "

anandamide

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

2

Fluorescent Dye

1

Biochemical Assay Reagents

9

Peptides

10

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10863
    Anandamide
    1 Publications Verification

    AEA

    		 Cannabinoid Receptor PPAR TRP Channel GPR55 Fungal Tau Protein Endogenous Metabolite Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .
    Anandamide
  • HY-125743
    S-1 Methanandamide

    (S)-Methanandamide

    		 Cannabinoid Receptor Neurological Disease
    S-1 Methanandamide ((S)-Methanandamide), an Anandamide analog, is a CB1 receptor ligand with a Ki of 173 nM. S-1 Methanandamide inhibits electrically-evoked twitch response in mouse vas deferens with an IC50 value of 230 nM .
    S-1 Methanandamide
  • HY-121476
    Arachidonoyl Serinol

    		MAGL Neurological Disease
    Arachidonoyl Serinol, an endogenous cannabimimetic metabolite, is an inhibitor of monoacylglycerol lipase (MAGL). Arachidonoyl Serinol inhibits the hydrolysis of [ 3H]2-oleoylglycerol and [ 3H]anandamide with IC50s of ～70 μM .
    Arachidonoyl Serinol
  • HY-10863S
    Anandamide-d8

    AEA-d8

    		 Isotope-Labeled Compounds Cannabinoid Receptor PPAR Endogenous Metabolite Tau Protein GPR55 Fungal TRP Channel Infection
    Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .
    Anandamide-d8
  • HY-10863S1
    Anandamide-d11

    AEA-d11

    		 Isotope-Labeled Compounds Cannabinoid Receptor GPR55 Endogenous Metabolite Inflammation/Immunology
    Anandamide-d11 is deuterium labeled Anandamide. Anandamide is an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55)[1][2].
    Anandamide-d11
  • HY-111293
    Arachidonamide

    Arachidonoyl amine; Arachidonic acid amide

    		 FAAH Metabolic Disease
    Arachidonamide is substrate of anandamide amidohydrolase .
    Arachidonamide
  • HY-123594
    R-2 Methanandamide

    		Cannabinoid Receptor Neurological Disease
    R-2 Methanandamide (Compound 2) is a cannabinoid Anandamide (HY-10863) analog with a Ki of 119 nM for the cannabinoid receptor (Ki is determined using rat brain membranes with PMSF) .
    R-2 Methanandamide
  • HY-113264
    PGD2 ethanolamide

    		Apoptosis Cancer
    PGD2 ethanolamide is the COX-2 dependent metabolite of Anandamide that induces apoptosis in colorectal carcinoma (CRC) cells .
    PGD2 ethanolamide
  • HY-103324
    Palmitoylisopropylamide

    PIA

    		 Others Metabolic Disease
    Palmitoylisopropylamide is a Palmitoylethanolamide analogue inhibits [ 3H]-Anandamide metabolism with a pI50 of 4.89 .
    Palmitoylisopropylamide
  • HY-115428
    (R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide

    		Cannabinoid Receptor Others
    (R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide (Compound 19) is the analogue of endogenous cannabinoid receptor ligand Anandamide (HY-10863). (R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide shows weak binding affinity for CB1 and CB2 with Kis of both 21 μM .
    (R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide
  • HY-101389
    (R)-Methanandamide

    AM-356

    		 Cannabinoid Receptor TRP Channel Neurological Disease
    (R)-Methanandamide (AM-356), an analog of the endocannabinoid ligand Anandamide, is a potent CB1 agonist with a Ki of 20 nM. (R)-Methanandamide also activates vanilloid (TRPV1) receptors .
    (R)-Methanandamide
  • HY-101388
    AM404
    2 Publications Verification

    		 Others Neurological Disease
    AM404, an inhibitor of endocannabinoid reuptake, blocks anandamide transport with IC50 values in the low micromolar range . AM404 is able to relax rat isolated hepatic arteries contracted with Phenylephrine, with a pEC50 value of 7.4 (corresponding to an EC50 of 0.04 μM). Neuroprotective Effect .
    AM404
  • HY-103332
    N-Arachidonylglycine
    1 Publications Verification

    NA-Gly

    		 GlyT Endogenous Metabolite Inflammation/Immunology
    N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC50 = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC50 = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .
    N-Arachidonylglycine
  • HY-10865
    LY2183240
    2 Publications Verification

    		 FAAH Autophagy Neurological Disease
    LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .
    LY2183240
  • HY-113421
    Linoleoyl ethanolamide

    Linoleic acid monoethanolamide

    		 Cannabinoid Receptor Neurological Disease
    Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .
    Linoleoyl ethanolamide
  • HY-110101
    ARN272

    		Others Neurological Disease
    ARN272 is an anandamide transport inhibitor .
    ARN272
  • HY-103338
    AM1172

    		FAAH Neurological Disease
    AM1172 is metabolically stable anandamide uptake inhibitor and FAAH inhibitor .
    AM1172
  • HY-103341
    UCM707

    		Cannabinoid Receptor Neurological Disease
    UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide .
    UCM707
  • HY-103340
    O-2093

    		Cannabinoid Receptor Neurological Disease
    O-2093 is a selective endocannabinoid anandamide (AEA) reuptake inhibitor with IC50 of 17.3 μM .
    O-2093
  • HY-135880A
    OMDM-4

    		Endogenous Metabolite Neurological Disease
    OMDM-4 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a Ki 17.7 μM .
    OMDM-4
  • HY-135880
    OMDM-3

    		Endogenous Metabolite Neurological Disease
    OMDM-3 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a Ki of 16.6 μM .
    OMDM-3
  • HY-121557
    OMDM-1

    		Endogenous Metabolite Neurological Disease
    OMDM-1 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a Ki of 2.4 μM .
    OMDM-1
  • HY-103342
    OMDM-2

    		Endogenous Metabolite Neurological Disease
    OMDM-2 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a Ki of 3.0 μM .
    OMDM-2
  • HY-134224
    Arachidonoyl 2'-fluoroethylamide

    		Others Endocrinology
    Arachidonoyl 2'-fluoroethylamide is an anandamide analog. Arachidonoyl 2'-fluoroethylamide has the potential for the research of intraocular hypertension .
    Arachidonoyl 2'-fluoroethylamide
  • HY-W337358
    N-(3-Hydroxyphenyl)-arachidonoyl amide

    		Others Neurological Disease
    N-(3-Hydroxyphenyl)-arachidonoyl amide (Compound 23) is an anandamide transport inhibitor with an IC50 of 21.3 μM .
    N-(3-Hydroxyphenyl)-arachidonoyl amide
  • HY-134110
    N-Methylarachidonamide

    		Endogenous Metabolite Metabolic Disease
    Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N-methyl amide is an analog of anandamide that binds to the human central cannabinoid (CB1) receptor with a Ki of 60 nM. It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
    N-Methylarachidonamide
  • HY-103334
    MAFP
    4 Publications Verification

    Methyl Arachidonyl Fluorophosphonate

    		 Phospholipase Cardiovascular Disease Neurological Disease Metabolic Disease
    MAFP (Methyl Arachidonyl Fluorophosphonate) is an selective, active-site directed and irreversible inhibitor of cPLA2 and iPLA2. MAFP is also a potent irreversible inhibitor of anandamide amidase.
    MAFP
  • HY-103507
    N-Arachidonyl-GABA

    		GABA Receptor Neurological Disease
    N-Arachidonoyl-GABA is one member of a new class of lipoamino acids related to anandamide identified in bovine brain. N-Arachidonoyl-GABA displays analgesic activity .
    N-Arachidonyl-GABA
  • HY-113516
    20-HETE Ethanolamide

    		Endogenous Metabolite Neurological Disease
    20-HETE Ethanolamide is a metabolite of endocannabinoid Anandamide. 20-HETE Ethanolamide binds to the rat brain cannabinoid CB1 receptor with a Ki of 985 nM .
    20-HETE Ethanolamide
  • HY-103339
    VDM11

    		FAAH MAGL Neurological Disease
    VDM11 is a potent and selective anandamide membrane transporter (AMT) inhibitor . VDM11 inhibits FAAH and MAGL and may act as an alternative FAAH substrate .
    VDM11
  • HY-134055
    Arachidonoyl-N,N-dimethyl amide

    Arachidonic acid-N,N-dimethyl amide

    		 Cannabinoid Receptor Metabolic Disease
    Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of anandamide that exhibits weak or no binding to the human central cannabinoid (CB1) receptor (Ki >1 μM). It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
    Arachidonoyl-N,N-dimethyl amide
  • HY-120957
    AMC Arachidonoyl Amide

    AMC-AA; 7-Amino-4-methyl coumarin-arachidonamide

    		 Endogenous Metabolite Metabolic Disease
    AMC arachidonoyl amide (AMC-AA) is one of several fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its nominal endogenous substrate anandamide.2 Exposure of AMC-AA to FAAH activity results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm. This allows the fast and convenient measurement of FAAH activity using a simple cuvette or microplate fluorometer.
    AMC Arachidonoyl Amide
  • HY-108455
    N-Palmitoyl dopamine

    PALDA

    		 Others Neurological Disease
    N-Palmitoyl dopamine (PALDA) is a endogenous, long-chain, linear fatty acid dopamide, which is inactive on TRPV1. N-Palmitoyl dopamine displays 'entourage' effects on endovanilloids N-arachidonoyl-dopamine (NADA) and anandamide .
    N-Palmitoyl dopamine
  • HY-120649
    SKM 4-45-1

    		Biochemical Assay Reagents Others
    SKM 4-45-1 is an analog of Anandamide (AEA)(HY-10863). SKM 4-45-1 is a fluorescent substrate, that can be used to study the transmembrane carrier-mediated transport of AEA across cell membranes .
    SKM 4-45-1
  • HY-116477
    URB937

    		FAAH Neurological Disease Inflammation/Immunology
    URB937 is an orally active and peripherally restricted FAAH inhibitor (IC50=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier) .
    URB937
  • HY-125967
    AM 374

    		FAAH Neurological Disease
    AM 374 is an fatty acid amide hydrolase (FAAH) inhibitor. AM 374 inhibits amidase activity with an IC50 value of 13 nM. AM 374 can be used for the research of neurological disease .
    AM 374
  • HY-19636A
    JNJ-42165279 dihydrochloride

    		FAAH Others
    JNJ-42165279 (dihydrochloride) is aFAAHinhibitor with IC50 of 70 nM and 313 nM for hFAAH and rFAAH, respectively .
    JNJ-42165279 dihydrochloride
  • HY-W127407
    Glycerophospho-N-arachidonoyl ethanolamine

    		Biochemical Assay Reagents Others
    Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.
    Glycerophospho-N-arachidonoyl ethanolamine
  • HY-P4154
    Bevonescein

    ALM-488

    		 Fluorescent Dye Neurological Disease
    Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
    Bevonescein
  • HY-135882
    OMDM-6

    		TRP Channel Cannabinoid Receptor Endogenous Metabolite Neurological Disease
    OMDM-6 is a hybrid agonist of vanilloid receptor type 1 (VR1, TRPV1) (EC50=75 nM) and cannabinoid receptor type 1 (CB1) (Ki=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a Ki of 7.0 μM .
    OMDM-6
  • HY-100197
    Synaptamide
    1 Publications Verification

    N-Docosahexaenoyl ethanolamine (DHEA); Docosahexaenoyl ethanolamide

    		 Cannabinoid Receptor Neurological Disease
    Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .
    Synaptamide
  • HY-P1103A
    CTCE-9908 TFA

    		CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    		 CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-135881
    OMDM-5

    		TRP Channel Endogenous Metabolite Neurological Disease
    OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a Ki of 4.8 μM. OMDM-5 is also a potent vanilloid receptor type 1 (VR1, TRPV1) agonist, with an EC50 of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (Ki=4.9 μM) .
    OMDM-5
  • HY-P2231A
    Cotadutide acetate
    1 Publications Verification

    MEDI0382 acetate

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide acetate
  • HY-131995
    O-Arachidonoyl glycidol

    		Cannabinoid Receptor Metabolic Disease
    O-Arachidonoyl glycidol (compound 1) is a 2-arachidonoylglycerol (2-AG) analog. O-Arachidonoyl glycidol inhibits cytosolic 2-oleoylglycerol (2-OG) hydrolysis with an IC50 value of 4.5 µM. O-Arachidonoyl glycidol blocks 2-OG hydrolysis in membrane fractions and anandamide hydrolysis with IC50s of 19, 12 µM, respectively .
    O-Arachidonoyl glycidol
  • HY-118140
    ZCZ011

    		Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    ZCZ011 is a potent and brain penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain .
    ZCZ011
  • HY-P2231
    Cotadutide
    1 Publications Verification

    MEDI0382

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide
  • HY-103332S
    N-Arachidonylglycine-d8

    NA-Gly-d8

    		 Isotope-Labeled Compounds Endogenous Metabolite GlyT Inflammation/Immunology
    N-Arachidonylglycine-d8 is a deuterated labeled N-Arachidonylglycine . N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC50 = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC50 = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .
    N-Arachidonylglycine-d8
  • HY-P1321
    GR231118

    1229U91; GW1229

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: